Compare UUU & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UUU | NCNA |
|---|---|---|
| Founded | 1969 | 1997 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 5.5M |
| IPO Year | 2025 | 2017 |
| Metric | UUU | NCNA |
|---|---|---|
| Price | $4.98 | $1.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 31.6K | ★ 59.6K |
| Earning Date | 02-19-2026 | 06-01-2026 |
| Dividend Yield | ★ 16.75% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,847,163.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.02 | $1.21 |
| 52 Week High | $7.82 | $7.01 |
| Indicator | UUU | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 49.61 | 41.24 |
| Support Level | $4.64 | $1.21 |
| Resistance Level | $6.23 | $1.41 |
| Average True Range (ATR) | 0.38 | 0.06 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 33.06 | 8.00 |
Universal Safety Products Inc designs and markets a variety of popularly priced safety products which, consisted mainly of smoke alarms, carbon monoxide alarms and related products. Its products require minimal installation and are designed for easy installation by the consumer without professional assistance and are sold through retail stores. It also market products to the electrical distribution trade. The electrical distribution trade includes electrical and lighting distributors as well as manufactured housing companies. Products it sell usually require professional installation. Its products are 2-in-1 Smoke & Fire Alarms, 3-in-1 Combo Alarms, and CO Alarms.
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.